CG Oncology, Inc. Common stock (CGON) NASDAQ
68.01
+0.835(+1.24%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
68.01
+0.835(+1.24%)
Currency In USD
| Previous Close | 67.18 |
| Open | 66.95 |
| Day High | 68.17 |
| Day Low | 65.57 |
| 52-Week High | 73.56 |
| 52-Week Low | 21 |
| Volume | 473,300 |
| Average Volume | 1.19M |
| Market Cap | 5.74B |
| PE | -32.7 |
| EPS | -2.08 |
| Moving Average 50 Days | 65.41 |
| Moving Average 200 Days | 46.27 |
| Change | 0.84 |
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
GlobeNewswire Inc.
Feb 27, 2026 1:30 PM GMT
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) N
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the TD Cowen 46th Annua
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
GlobeNewswire Inc.
Jan 09, 2026 1:30 PM GMT
- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial to evaluate an investigational therapy in intermedia